These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 2504895

  • 1. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR, O'Sullivan EJ, Hubbell EA, Zucker MJ, Pifarre R, McManus BM, Winters GL, Scanlon PJ, Robinson JA.
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [Abstract] [Full Text] [Related]

  • 2. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
    Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Winters GL, Pifarre R, Radvany R, Zucker MJ, Scanlon PJ, Robinson JA.
    J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
    [Abstract] [Full Text] [Related]

  • 3. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP, Frazier OH, Lammermeier D, Radovancevic B, Duncan JM.
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [Abstract] [Full Text] [Related]

  • 4. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK, Bourge RC, White-Williams C, Naftel DC, Thomas FT, Thomas JM, Phillips MG.
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [Abstract] [Full Text] [Related]

  • 5. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML, Sanchez JA, Seche LA, Schulman LL, Smith CR, Rose EA.
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [Abstract] [Full Text] [Related]

  • 6. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
    Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR.
    J Heart Transplant; 1989 Nov; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
    [Abstract] [Full Text] [Related]

  • 7. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 8. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M, Lake KD, Pritzker MR, Jorgensen CR, Arom KV, Love KR, Emery RW.
    J Heart Lung Transplant; 1991 Aug; 10(6):901-11. PubMed ID: 1661608
    [Abstract] [Full Text] [Related]

  • 9. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP, Kormos RL, Armitage JM, Dummer JS, Hardesty RL.
    J Heart Transplant; 1990 Aug; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [Abstract] [Full Text] [Related]

  • 10. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
    Kormos RL, Herlan DB, Armitage JM, Stein K, Kaufman C, Zeevi A, Duquesnoy R, Hardesty RL, Griffith BP.
    J Heart Transplant; 1990 Aug; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
    [Abstract] [Full Text] [Related]

  • 11. Prophylactic OKT3 used as induction therapy for heart transplantation.
    Starnes VA, Oyer PE, Stinson EB, Dein JR, Shumway NE.
    Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
    [Abstract] [Full Text] [Related]

  • 12. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [Abstract] [Full Text] [Related]

  • 13. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, Melvin DB.
    J Heart Transplant; 1989 Nov; 8(5):371-80. PubMed ID: 2529358
    [Abstract] [Full Text] [Related]

  • 14. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 15. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
    McNamara D, Di Salvo T, Mathier M, Keck S, Semigran M, Dec GW.
    J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
    [Abstract] [Full Text] [Related]

  • 16. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt CW, Jones KW, Gay WA, Menlove RL, Bristow MR.
    J Heart Lung Transplant; 1991 May; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [Abstract] [Full Text] [Related]

  • 17. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3.
    Kemnitz J, Cremer J, Schaefers HJ, Restrepo-Specht I, Haverich A, Uysal A, Heublein B, Wirth S.
    J Heart Lung Transplant; 1991 May; 10(3):366-72. PubMed ID: 1906746
    [Abstract] [Full Text] [Related]

  • 18. OKT3 treatment of cardiac allograft rejection.
    Haverty TP, Sanders M, Sheahan M.
    J Heart Lung Transplant; 1993 May; 12(4):591-8. PubMed ID: 8369321
    [Abstract] [Full Text] [Related]

  • 19. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A, Gallino A, Schneider J, Bauer EP, Carrel T, Pasic M, von Segesser LK, Turina MI.
    J Heart Lung Transplant; 1992 May; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [Abstract] [Full Text] [Related]

  • 20. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
    Frist WH, Merrill WH, Eastburn TE, Atkinson JB, Stewart JR, Hammon JW, Bender JW.
    J Heart Transplant; 1990 May; 9(5):489-94. PubMed ID: 2121921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.